Name
Purdue University Globle
NU505 Clinical Epidemiology and Population Health Promotion
Prof. Name
Date
An abdominal aortic aneurysm (AAA) is an abnormal enlargement of the abdominal portion of the aorta caused by weakening of the artery wall. Most AAAs develop gradually without symptoms, so targeted screening is important for people at increased risk. The U.S. Preventive Services Task Force (USPSTF) recommends a one-time abdominal ultrasound for men ages 65 to 75 who have ever smoked. Management depends primarily on aneurysm size, growth rate, symptoms, rupture risk, and the patient’s overall health.
AAA is a serious vascular condition because an enlarging aneurysm can eventually rupture and cause massive internal bleeding. Early detection allows healthcare professionals to monitor smaller aneurysms and consider elective repair before rupture occurs.
An abdominal aortic aneurysm occurs when a weakened area of the abdominal aorta becomes enlarged. The aorta is the body’s largest artery and carries oxygen-rich blood from the heart to the abdomen, pelvis, and lower extremities.
An aneurysm generally develops slowly. As the aortic wall loses structural strength, blood pressure places continued stress on the weakened area, causing it to expand. Many people do not experience symptoms while an aneurysm is small, which is why AAA is frequently discovered during screening or imaging performed for another medical condition.
A ruptured AAA is a medical emergency. Severe internal bleeding can lead to shock, organ failure, and death unless emergency treatment is provided immediately.
There is no single cause of AAA. The condition develops through a combination of age-related changes, inflammation, vascular injury, genetic susceptibility, and cardiovascular risk factors.
As the aortic wall becomes weaker, structural components such as collagen and elastin can deteriorate. Chronic inflammation and other biological processes may further contribute to destruction of the connective tissue that gives the aorta its strength and elasticity.
Factors involved in AAA development may include:
Chronic inflammation of the aortic wall
Degeneration of connective tissue
Atherosclerosis and vascular injury
Oxidative stress
Genetic susceptibility
Long-term cardiovascular disease
Age-related weakening of the arterial wall
Genetic research has identified several variants associated with susceptibility to AAA. Genome-wide association studies have identified loci involving genes such as CDKN2B-AS1, DAB2IP, LRP1, LDLR, and SORT1, providing additional insight into the biological mechanisms involved in aneurysm development (Roychowdhury et al., 2023).
The risk of AAA increases with age and is particularly high among older men and people with a history of tobacco use. Some risk factors can be modified, while others cannot.
Important AAA risk factors include:
Cigarette smoking or a history of smoking
Older age, particularly 65 years and above
Male sex
Family history of AAA
Hypertension
Atherosclerotic cardiovascular disease
High cholesterol
Obesity
Certain genetic factors
A person’s overall risk generally increases when several of these factors occur together.
Smoking is one of the most important preventable risk factors for abdominal aortic aneurysm. Tobacco exposure can damage blood vessels, promote inflammation, accelerate atherosclerosis, and contribute to the breakdown of connective tissue within the aortic wall.
Both current and former smokers have a substantially greater risk of developing AAA than people who have never smoked. Smoking is also associated with aneurysm growth and an increased risk of rupture.
Smoking cessation is therefore an important part of AAA prevention and management. Quitting does not reverse an existing aneurysm, but it can reduce continued vascular injury and improve overall cardiovascular health.
AAA primarily affects older adults, with a higher prevalence among men than women. The likelihood of developing an aneurysm increases substantially with advancing age.
Although AAA prevalence has declined in some populations alongside reductions in smoking rates and improvements in cardiovascular disease management, it remains an important cause of preventable vascular mortality.
U.S. population data and screening studies have identified older men, particularly those with smoking exposure and other cardiovascular risk factors, as an important high-risk group.
The prevalence of AAA can vary considerably depending on the population studied, age distribution, sex, smoking history, and definition used for an aneurysm. For this reason, prevalence estimates from individual studies should not be assumed to represent every population.
The people at greatest risk generally include older men who have smoked, individuals with a family history of AAA, and people with multiple cardiovascular risk factors.
A large U.S. screening study involving 9,457 participants found that AAA prevalence was associated with several established cardiovascular risk factors. Approximately 2.82% of participants had an abdominal aortic diameter greater than 3 cm, with prevalence approaching 3% among men ages 65 to 75 (Summers et al., 2019).
Family history is also clinically important. People with a first-degree relative who has had an AAA may have a higher risk and should discuss individualized screening with a healthcare professional.
Screening for AAA is performed primarily with abdominal ultrasonography. Ultrasound is noninvasive, does not expose patients to ionizing radiation, is relatively inexpensive, and provides accurate measurements of the abdominal aorta.
The USPSTF recommends:
Men ages 65 to 75 who have ever smoked: One-time abdominal ultrasound screening is recommended.
Men ages 65 to 75 who have never smoked: Screening should be considered selectively based on individual circumstances and risk factors.
Women who have never smoked and have no family history of AAA: Routine screening is not recommended because the expected benefit is small.
Women ages 65 to 75 who have smoked: Evidence is currently insufficient for the USPSTF to determine whether routine screening provides a net benefit.
Screening decisions should be individualized when a patient has significant risk factors, particularly a strong family history or substantial cardiovascular disease.
Abdominal ultrasound is the preferred screening test because it is accurate, safe, widely available, and does not require radiation exposure.
The USPSTF evidence review found that ultrasound has very high diagnostic accuracy for detecting AAA, with reported sensitivity of approximately 94% to 100% and specificity of approximately 98% to 100% (Guirguis-Blake et al., 2019).
Ultrasound can also be used for surveillance after an aneurysm has been identified.
Many AAAs are discovered before symptoms occur. A patient may undergo an ultrasound as part of screening or have an aneurysm identified incidentally during imaging performed for another medical concern.
Once an aneurysm is identified, clinicians assess several characteristics, including:
Maximum aneurysm diameter
Location and anatomy
Growth rate
Presence or absence of symptoms
Overall cardiovascular health
Risk of rupture
Suitability for surgical or endovascular repair
Computed tomography (CT), particularly CT angiography, may be used when more detailed anatomical information is required. CT imaging is especially useful for preoperative planning or when rupture or another acute vascular complication is suspected.
Small AAAs frequently cause no symptoms. When symptoms occur, they may include persistent abdominal discomfort, back pain, or a pulsating sensation in the abdomen.
A ruptured AAA can produce sudden and severe symptoms, including:
Sudden severe abdominal or back pain
Dizziness or fainting
Weakness
Rapid heart rate
Low blood pressure
Loss of consciousness
Signs of circulatory shock
Suspected rupture requires immediate emergency medical treatment.
No. Many small AAAs do not require immediate surgery. Instead, they are monitored through periodic imaging while cardiovascular risk factors are addressed.
For many patients, active surveillance is safer than exposing them to the risks of early surgery when the aneurysm is small and asymptomatic.
Treatment decisions depend on:
Aneurysm size
Rate of growth
Symptoms
Evidence of impending rupture
Patient age
Overall health
Surgical risk
Aortic anatomy
Small, asymptomatic AAAs are generally managed through surveillance and cardiovascular risk reduction.
Management may include regular imaging to monitor aneurysm size and growth. The interval between examinations depends on the aneurysm’s size and clinical circumstances.
Patients may also be advised to:
Stop smoking
Control blood pressure
Manage cholesterol
Maintain a healthy weight
Remain physically active as medically appropriate
Follow prescribed cardiovascular medications
Attend scheduled imaging appointments
Lifestyle changes cannot make an established aneurysm disappear, but they are important for reducing overall cardiovascular risk and may help limit factors associated with aneurysm progression.
Elective repair is generally considered when an aneurysm reaches a size at which the expected risk of rupture becomes greater than the risks associated with repair. Repair may also be recommended when an aneurysm causes symptoms, grows rapidly, or shows other concerning characteristics.
For many asymptomatic men, elective repair is commonly considered when an AAA reaches approximately 5.5 cm, although the decision must be individualized.
Women and patients with unusual anatomy or other risk factors may require different considerations. Clinical judgment and current vascular surgery guidelines should guide treatment decisions.
Open surgical repair is a traditional treatment in which the weakened section of the aorta is repaired using a synthetic graft.
The procedure generally requires a larger abdominal incision and has a longer recovery period than endovascular repair. However, open repair has demonstrated long-term durability and remains an important treatment option, particularly for patients whose anatomy is unsuitable for endovascular repair.
Endovascular aneurysm repair, commonly called EVAR, is a minimally invasive procedure used to treat eligible abdominal aortic aneurysms.
During EVAR, a stent graft is introduced through an artery, usually through the femoral arteries in the groin. The graft is positioned inside the aorta so that blood flows through the graft rather than directly against the weakened aneurysm wall.
Potential advantages include:
Smaller incisions
Shorter initial recovery
Shorter hospital stay
Less postoperative discomfort in many patients
Lower short-term physiologic stress compared with open repair
EVAR also has limitations. Patients require long-term imaging surveillance because complications such as endoleaks, graft migration, or other device-related problems can occur.
The choice between EVAR and open repair depends on the patient’s anatomy, age, health status, operative risk, life expectancy, and preferences.
EVAR may offer advantages during the early recovery period, while open repair can provide greater long-term durability in some circumstances. Neither procedure is universally best for every patient.
A vascular surgeon typically evaluates imaging studies and the patient’s overall health before recommending an approach.
Research has generally shown that immediate elective repair does not provide a clear survival advantage over careful surveillance for many patients with small, asymptomatic AAAs.
Landmark randomized trials comparing early surgery with surveillance for aneurysms measuring approximately 4.0 to 5.4 cm found that routine early repair did not significantly improve overall outcomes for most patients in this size range (Lederle et al., 2002).
These findings support surveillance as an appropriate strategy for many patients with smaller aneurysms.
The goal is to identify the point at which the risk of rupture becomes greater than the risks associated with elective repair.
Several large randomized trials have demonstrated the value of targeted AAA screening, particularly among older men.
The Multicentre Aneurysm Screening Study (MASS) found that ultrasound screening of men substantially reduced AAA-related mortality during long-term follow-up (Ashton et al., 2002).
Other population-based screening programs, including studies conducted in Denmark, the United Kingdom, and Australia, have provided additional evidence that identifying AAAs before rupture allows patients to undergo surveillance or planned repair rather than emergency treatment.
The overall evidence supports targeted screening rather than universal screening of the entire adult population.
Surveillance allows healthcare professionals to monitor aneurysm growth and identify patients who may eventually benefit from intervention.
Long-term follow-up is particularly important because an aneurysm that is small and stable at one examination may enlarge over time.
An 11-year follow-up study of men screened at age 65 demonstrated the long-term value of structured AAA screening and follow-up, with most aneurysms detected before rupture and relatively few patients ultimately requiring emergency treatment (Mansoor et al., 2023).
AAA research is increasingly focused on identifying which aneurysms are most likely to grow or rupture. Current investigations include genetics, biomarkers, advanced imaging, artificial intelligence, and new medical treatments.
Researchers are particularly interested in developing ways to distinguish aneurysms that are likely to remain stable from those that require closer monitoring or earlier intervention.
Genetic research has identified multiple regions of the genome associated with AAA susceptibility. Findings involving CDKN2B-AS1, DAB2IP, LRP1, LDLR, and SORT1 have improved understanding of the biological pathways involved in aneurysm formation (Roychowdhury et al., 2023).
Researchers are also investigating PCSK9 as a potential therapeutic target.
In the future, genetic information may be combined with age, smoking history, family history, blood pressure, cholesterol, and imaging findings to create more individualized AAA risk assessments.
Researchers are studying blood-based and molecular biomarkers that could potentially help identify aneurysm development, predict growth, or estimate rupture risk.
Biomarkers under investigation include molecules associated with inflammation, vascular remodeling, and connective-tissue degradation.
However, these approaches remain primarily research tools and should not currently replace established ultrasound screening or clinical surveillance.
Artificial intelligence and machine learning are emerging areas of interest in vascular medicine. Researchers are investigating whether these technologies can improve interpretation of ultrasound and CT images and identify patterns associated with aneurysm growth or rupture.
Potential applications include:
Automated aneurysm measurement
Detection of subtle changes in aneurysm size
Risk prediction
Surgical planning
Imaging follow-up
Personalized surveillance recommendations
AI-assisted AAA management remains an evolving field and requires continued clinical validation before widespread routine use.
Researchers are investigating whether medications could slow aneurysm expansion and reduce the need for surgery. Potential approaches include therapies targeting inflammation, vascular remodeling, oxidative stress, and connective-tissue degradation.
Improved endovascular devices and more individualized surveillance strategies are also being developed.
At present, however, no medication has replaced surveillance or surgical repair when intervention is clinically indicated.
Nurses, physicians, and other healthcare professionals have an important role in identifying patients who may benefit from screening and reducing modifiable cardiovascular risk.
Clinical care should emphasize:
Identifying eligible patients for AAA screening
Taking a detailed smoking history
Assessing family history
Monitoring blood pressure and cholesterol
Promoting smoking cessation
Reinforcing adherence to surveillance imaging
Recognizing symptoms of possible rupture
Coordinating referral to vascular specialists when appropriate
Patient education is particularly important because AAA can remain asymptomatic for years.
Abdominal aortic aneurysm is a potentially fatal vascular condition caused by weakening and enlargement of the abdominal aorta. Because most AAAs are asymptomatic until they become advanced or rupture, screening high-risk populations is an important prevention strategy.
The most important points are:
Smoking is the strongest modifiable risk factor for AAA.
Risk increases substantially with age.
Men are affected more frequently than women.
Family history can increase AAA risk.
Abdominal ultrasound is the preferred screening test.
The USPSTF recommends one-time screening for men ages 65 to 75 who have ever smoked.
Many small, asymptomatic aneurysms can be managed with surveillance.
Rapidly enlarging, symptomatic, or sufficiently large aneurysms may require repair.
EVAR provides a minimally invasive treatment option for anatomically suitable patients.
Open repair remains an important treatment approach.
Genetics, biomarkers, advanced imaging, and artificial intelligence are active areas of AAA research.
Early identification, smoking cessation, cardiovascular risk management, appropriate surveillance, and timely referral for repair remain central to reducing AAA-related morbidity and mortality.
AAA does not have one single cause. It develops through a combination of weakening of the aortic wall, aging, inflammation, cardiovascular disease, smoking, genetic susceptibility, and other risk factors. Smoking is the most important modifiable risk factor.
The USPSTF recommends a one-time abdominal ultrasound for men ages 65 to 75 who have ever smoked. Screening may be considered selectively for men in this age group who have never smoked based on individual risk factors. Routine screening is not recommended for women who have never smoked and have no family history of AAA.
Abdominal ultrasound is the preferred screening test because it is accurate, noninvasive, inexpensive, and does not expose the patient to radiation.
For many asymptomatic men, elective repair is commonly considered when the aneurysm reaches approximately 5.5 cm. However, aneurysm size is not the only consideration. Symptoms, growth rate, anatomy, sex, overall health, and surgical risk also influence the treatment decision.
An established AAA does not normally disappear on its own. Small aneurysms may remain stable for years, while others gradually enlarge. Regular surveillance is therefore important.
Yes. Smoking is strongly associated with AAA development, aneurysm growth, and rupture risk. Quitting smoking is one of the most important steps a person with an AAA can take to improve vascular health.
It can be. A small, stable AAA may have a relatively low immediate risk, but the risk increases as the aneurysm enlarges. Rupture can cause life-threatening internal bleeding and requires emergency treatment.
Yes. AAA is less common in women than men, but women can develop the condition. Smoking, older age, cardiovascular disease, and family history can increase risk.
Physical activity may be appropriate for many people with small, stable AAAs, but exercise recommendations should be individualized. Patients should discuss the appropriate intensity and type of exercise with their healthcare professional.
A ruptured AAA can cause sudden severe abdominal or back pain, internal bleeding, low blood pressure, dizziness, fainting, and shock. It is a life-threatening emergency requiring immediate medical attention.
Ashton, H. A., Buxton, M. J., Day, N. E., Kim, L. G., Marteau, T. M., Scott, R. A. P., Thompson, S. G., & Walker, N. M. (2002). The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: A randomised controlled trial. The Lancet, 360(9345), 1531–1539. https://doi.org/10.1016/S0140-6736(02)11522-4
Guirguis-Blake, J. M., Beil, T. L., Senger, C. A., & Coppola, E. L. (2019). Primary care screening for abdominal aortic aneurysm: Updated evidence report and systematic review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality. https://www.ncbi.nlm.nih.gov/books/NBK551974/
Lederle, F. A., Wilson, S. E., Johnson, G. R., Reinke, D. B., Littooy, F. N., Acher, C. W., Ballard, D. J., Messina, L. M., Gordon, I. L., Chute, E. P., Krupski, W. C., Ansel, H. J., Barner, H. B., & Makaroun, M. S. (2002). Immediate repair compared with surveillance of small abdominal aortic aneurysms. The New England Journal of Medicine, 346(19), 1437–1444. https://doi.org/10.1056/NEJMoa012573
Mansoor, S. M., Rabben, T., Hisdal, J., & Jørgensen, J. J. (2023). Eleven-year outcomes of a screening project for abdominal aortic aneurysm in 65-year-old men. Vascular Health and Risk Management, 19, 459–467. https://doi.org/10.2147/VHRM.S412954
Roychowdhury, T., Klarin, D., Levin, M. G., et al. (2023). Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. Nature Genetics, 55(11), 1831–1842. https://doi.org/10.1038/s41588-023-01510-y
Summers, K. L., Kerut, E. K., Sheahan, C., et al. (2019). Prevalence of abdominal aortic aneurysms in the United States: Reevaluating the screening guidelines. Journal of Vascular Surgery, 70(3). https://doi.org/10.1016/j.jvs.2019.06.120
U.S. Preventive Services Task Force. (2019). Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. JAMA, 322(22), 2211–2218. https://doi.org/10.1001/jama.2019.18928
Vardulaki, K. A., Walker, N. M., Day, N. E., Duffy, S. W., Ashton, H. A., & Scott, R. A. P. (2000). Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. British Journal of Surgery, 87(2), 195–200. https://doi.org/10.1046/j.1365-2168.2000.01353.x
Zucker, E. J., & Prabhakar, A. M. (2018). Abdominal aortic aneurysm screening: Concepts and controversies. Cardiovascular Diagnosis and Therapy, 8(Suppl. 1), S108–S117. https://doi.org/10.21037/cdt.2017.09.13
